| Trial ID: | L0827 |
| Source ID: | NCT03452189
|
| Associated Drug: |
Vancomycin
|
| Title: |
The Effect of an Antibiotic on the Production of Uremic Toxins by the Gut Microbiome
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT03452189/results
|
| Conditions: |
End Stage Renal Disease
|
| Interventions: |
DRUG: Vancomycin|OTHER: Placebo
|
| Outcome Measures: |
Primary: Change in Plasma Concentration Measure of Indoxyl Sulphate (IS), Plasma concentrations of IS were measured by HPLC (high pressure liquid chromatography). Assessed weekly between day 0 and Week 4; change from baseline/day 0 to Week 4 reported, 4 weeks|Change in Plasma Concentration Measure P-Cresyl Sulphate (PCS), Plasma concentrations of P-Cresyl Sulphate (PCS) were measured by HPLC (high pressure liquid chromatography) Assessed weekly between day 0 and Week 4; change from baseline/day 0 to Week 4 reported, 4 weeks |
|
| Sponsor/Collaborators: |
Sponsor: NYU Langone Health
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
15
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT
|
| Start Date: |
2017-11-27
|
| Completion Date: |
2018-08-18
|
| Results First Posted: |
2021-03-26
|
| Last Update Posted: |
2021-03-26
|
| Locations: |
New York University School of Medicine, New York, New York, 10016, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT03452189
|
